Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals Inc. (KPRX) reported that executive Keith J. Lane, EVP, Clinical and Regulatory, received a grant of stock options for 55,000 shares of Common Stock on September 17, 2026. The options have an exercise price of $2.67 per share and expire on September 17, 2036.
According to the award terms, the option becomes exercisable as to one-third of the shares on September 17, 2027, with the remaining balance vesting monthly on the last day of each month over the following two years, subject to Mr. Lane’s continuous service. No Rule 10b5-1 trading plan is reported for this grant.
Kiora Pharmaceuticals Inc (KPRX) reported an initial statement of beneficial ownership on Form 3 for Lane Keith J., identified as "EVP, Clinical and Regulatory." The filing reports no equity transactions or derivative positions and lists no specific holdings for this reporting person as of the filing date.
KIORA PHARMACEUTICALS, INC. (KPRX) has a new significant shareholder group reporting on a passive basis under Schedule 13G. Baselake Partners, LP, together with Baselake Management, LLC and David Paolella (collectively, the reporting persons), report beneficial ownership of 257,500 shares of Kiora common stock, representing 5.8% of the class.
The filing explains that the shares are held directly by Baselake Partners, LP, with Baselake Management, LLC as investment manager and David Paolella as managing member. All three reporting persons are deemed to share voting and dispositive power over these shares, but each disclaims beneficial ownership beyond their pecuniary interest. The percentage ownership is calculated based on 4,424,387 shares outstanding as of August 5, 2026, as disclosed in Kiora’s Form 10-Q.
Kiora Pharmaceuticals, Inc. (KPRX) appointed Keith J. Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs effective September 8, 2026. Lane brings over 20 years of ophthalmology-focused clinical development and regulatory experience, including leadership at Ora, Inc. and oversight of more than 60 ophthalmic clinical trials.
Under a June 22, 2026 Offer Letter, Lane will receive a $350,000 annual base salary, a $75,000 sign-on bonus, and is eligible for an annual performance bonus targeted at up to 35% of base salary. Subject to Compensation Committee approval under the 2024 Equity Incentive Plan, he will be granted an option to purchase up to 55,000 shares of Kiora common stock, vesting one-third on the first anniversary of the grant and monthly over the following two years. Kiora also furnished a press release announcing the hiring as an exhibit.
Kiora Pharmaceuticals, Inc. (KPRX) entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation (CKD) covering its KIO-301 molecular photoswitch program. CKD receives an exclusive, sublicensable license to develop, manufacture, commercialize and seek regulatory approvals for KIO-301 in South Korea for retinitis pigmentosa and other ophthalmic diseases.
Under the agreement, Kiora will receive a $1 million up-front payment and is eligible for additional development, regulatory and sales milestone payments, plus double digit royalties on net sales in South Korea, subject to adjustments. CKD will lead development and commercialization in South Korea, while Kiora expects CKD, Laboratoires Théa and Senju Pharmaceutical to coordinate a single global Phase 3 trial for KIO-301 in retinitis pigmentosa.
Kiora highlights that this deal fills the last major unpartnered market for KIO-301 and allows internal resources to focus on KIO-104 for retinal inflammation and fibrosis and evaluation of ion channel modulators for non-ophthalmic uses, alongside potential strategic pipeline-expansion transactions.
ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC and Daniel Schneeberger report beneficial ownership of Kiora Pharmaceuticals common stock. Each Reporting Person discloses beneficial ownership of approximately 9.9% of the outstanding common stock, based on 4,427,167 shares outstanding as of June 30, 2026.
The reported positions include combinations of directly held shares and shares underlying pre-funded and milestone warrants, while additional warrant shares are excluded due to a 9.99% beneficial ownership limitation. Schneeberger files as a control person over the ADAR1 entities.
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of Kiora Pharmaceuticals, Inc. common stock. As of June 30, 2026, they may be deemed to beneficially own 491,889 shares, including shares acquirable within sixty days through convertible securities. This position represents 9.99% of Kiora’s outstanding common stock for each reporting person. All voting and dispositive power over these shares is reported as shared, with no sole voting or dispositive power. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, has rights to receive dividends or sale proceeds on more than five percent of the outstanding common stock included in this beneficial ownership.
Kiora Pharmaceuticals, Inc. is reported to have 9.99% of its common stock beneficially owned by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd., acting together. This filing corrects and restates a prior ownership report that was submitted under an incorrect Central Index Key.
The Master Fund directly holds 438,471 shares of common stock, pre-funded warrants to purchase 1,134,474 shares at an exercise price of $0.0001 per share, and common warrants to purchase 7,864,726 shares at $1.94 per share. Warrant terms limit exercises so that the reporting group cannot beneficially own more than 9.99% of the outstanding shares, which currently permits exercise of warrants for up to 3,916 shares. Reported ownership and percentages are based on 4,424,387 shares of common stock outstanding as of August 5, 2026.
Kiora Pharmaceuticals reported financial results for the second quarter ended June 30, 2026, alongside updates on its retinal-disease pipeline. Enrollment has advanced into the higher 100 µg dose cohort of the Phase 2 ABACUS-2 trial of KIO-301 for late-stage retinitis pigmentosa, with an independent safety review planned after the first few higher-dose patients are treated. The company expects the last patient, first visit in the first quarter of 2027 and topline data in the third quarter of 2027. Development costs for ABACUS-2 are fully reimbursed under Kiora’s collaboration with Théa Open Innovation, which holds exclusive rights to KIO-301 in the U.S., Europe and other select territories outside Asia.
For KIO-104, a non-steroidal DHODH inhibitor for retinal inflammation and macular edema, patients are being enrolled into the higher-dose group of the Phase 2 KLARITY trial, with initial clinical data expected in late 2026. Kiora is also evaluating potential strategic transactions to diversify its pipeline, which could trigger warrant exercises linked to a recent financing, and is assessing partnering options across Asian territories, including an option agreement with Senju and a potential commercial partner in South Korea.
Kiora ended the quarter with approximately $16.8 million in cash and short-term investments, up from $13.9 million at March 31, 2026, and has secured a private placement for up to $24.0 million in gross proceeds, including $5.0 million already received. Based on its operating plan, collaboration reimbursements and available capital, the company expects to fund operations into late 2028. Research and development expenses were $2,077,116 before $1,336,263 in collaboration credits, general and administrative expenses were $1,383,504, and net loss was $2,079,010, or $0.34 per share, for the second quarter of 2026.
Kiora Pharmaceuticals, a clinical-stage ophthalmic company, reported a net loss of $2,079,010 for the quarter and $4,496,994 for the six months ended June 30, 2026. Quarterly operating expenses were $2.2M, including $2.1M of research and development, partially offset by $1.3M of collaboration credits from the KIO‑301 partnership.
Cash, cash equivalents and restricted cash totaled $7.1M and short-term investments $9.8M as of June 30, 2026, with total assets of $23.8M and stockholders’ equity of $16.9M. Management states that, based on these cash resources, it anticipates funding planned operations into late 2028 and does not currently anticipate an immediate need to raise additional capital.
The pipeline centers on KIO‑301, a potential vision-restoring small-molecule photoswitch for degenerative retinal diseases partnered with Théa Open Innovation, and KIO‑104, an intravitreal DHODH inhibitor in Phase 2 for retinal inflammation. Under the Théa license, all KIO‑301 research and development costs are reimbursed.